Morning Briefing
Summaries of health policy coverage from major news organizations
MenAfriVac More Effective, Less Expensive Than Older Meningitis Vaccines, Studies Say
The meningococcal vaccine MenAfriVac, which is made by the Indian generic drug company Serum Institute, is "dramatically better" at producing a protective effect among African children in three countries than "older so-called meningococcal polysaccaride vaccines, including Mencevax from GlaxoSmithKline," according to a paper describing two studies published in the New England Journal of Medicine, Reuters reports.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
